

1 **2018 EUROPEAN THYROID ASSOCIATION (ETA) GUIDELINES ON THE**
2 **DIAGNOSIS AND MANAGEMENT OF CENTRAL HYPOTHYROIDISM (CeH)***

3

4 Luca Persani^{1,2}, Georg Brabant³, Mehul Dattani⁴, Marco Bonomi^{1,2}, Ulla Feldt-Rasmussen⁵,
5 Eric Fliers⁶, Annette Gruters⁷, Dominique Maiter⁸, Nadia Schoenmakers⁹, Paul van
6 Trotsenburg¹⁰

7 ¹*Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy;*

8 ²*Division of Endocrine and Metabolic Diseases, IRCCS Istituto Auxologico Italiano, Milan,*
9 *Italy*

10 ³*Experimental and Clinical Endocrinology Medical Clinic I - University of Luebeck, Luebeck,*
11 *Germany*

12 ⁴*Genetics and Genomic Medicine Programme, UCL GOS Institute of Child Health, London,*
13 *UK*

14 ⁵*Department of Medical Endocrinology and Metabolism, Rigshospitalet, Copenhagen*
15 *University Hospital, Copenhagen, Denmark*

16 ⁶*Department of Endocrinology and Metabolism, Academic Medical Center, University of*
17 *Amsterdam, The Netherlands*

18 ⁷*Department for Pediatric Endocrinology and Diabetes, Charité University Medicine,*
19 *Berlin, Germany and University Hospital Heidelberg, Germany*

20 ⁸*Department of Endocrinology and Nutrition, UCL Cliniques Saint-Luc, Brussels, Belgium*

21 ⁹*University of Cambridge Metabolic Research Laboratories, Wellcome Trust-Medical*
22 *Research Council Institute of Metabolic Science, Addenbrooke's Hospital and National*
23 *Institute for Health Research Cambridge Biomedical Research Centre, Addenbrooke's*
24 *Hospital, Cambridge, UK*

25 ¹⁰*Department of Pediatric Endocrinology, Emma Children's Hospital, Academic Medical*
26 *Center, University of Amsterdam, The Netherlands*

27

28 *These ETA guidelines have been endorsed by the European Society of Pediatric
29 Endocrinology (ESPE) and by the European Reference Network for Rare Endocrine
30 Conditions (ENDO-ERN).

31

32 **Words in text:** 3245 (without references).

33

34 **CONFLICT OF INTEREST:** All the experts declare no conflict of interest related to the
35 content of the guidance.

36

37 **KEY WORDS:** central hypothyroidism – thyroxine – Thyrotropin – TRH - pituitary –
38 thyroid – subclinical hypothyroidism – guidelines – hormone replacement therapy

39 **Running title:** ETA guidelines for CeH

40

41 **Corresponding Author:**

42 *Prof Luca Persani, MD PhD*

43 *University of Milan & IRCCS Istituto Auxologico Italiano,*

44 *San Luca Hospital*

45 *Piazzale Brescia 20 – 20149 Milan, Italy*

46 *Email: luca.persani@unimi.it*

47 **ABSTRACT**

48 Central Hypothyroidism (CeH) is a rare form of hypothyroidism characterized by insufficient
49 thyroid stimulation due to disturbed pituitary and/or hypothalamic functioning. Due to its
50 origin and the whole clinical context, CeH represents a challenging condition in clinical
51 practice as it is characterized by suboptimal accuracy of clinical and biochemical parameters
52 for diagnosis and management. Since no expert consensus or guidance for this condition is
53 currently available, a task force of experts received the commitment from the European
54 Thyroid Association (ETA) to prepare this document based on the principles of clinical
55 evidence. The task force started to work in February 2017 and after 1-year work, a
56 preliminary presentation and live discussion during the 2017 ETA meeting, and several
57 revision rounds has prepared a list of recommendations to support the diagnosis and
58 management of patients with CeH. Due to the particular challenges of this rare condition in
59 the different ages, the target users of this guidance are pediatric and adult Endocrinologists.
60 Experts agreed on the need to recognize and treat overt CeH at all ages, whereas treatment of
61 milder forms may be dispensable in the elderly (>75 years). Despite the lack of randomized
62 controlled clinical trials, the experts provide 34 recommendations supported by variable levels
63 of strength that should improve the quality of life of the affected patients and reduce the
64 metabolic and hormonal consequences of inadequate management.

65

66

67 INTRODUCTION

68 Central hypothyroidism (CeH) is a disorder characterized by defective thyroid hormone
69 production due to insufficient stimulation by thyrotropin (TSH) of an otherwise normal
70 thyroid gland. This condition is the consequence of anatomic or functional disorders of the
71 pituitary gland (secondary hypothyroidism) or the hypothalamus (tertiary hypothyroidism)
72 causing variable alterations of TSH secretion [1,2]

73 The failure of thyrotrope cells is frequently part of multiple pituitary hormone
74 deficiency (MPHD), a condition complicating both diagnosis and clinical management of
75 CeH. Congenital CeH can be moderate to severe in approximately half of the cases and
76 consequently affect neurodevelopment [3]. In these cases, a delayed onset of treatment causes
77 irreversible neurological defects. More frequently, diagnosis is made biochemically and
78 should be suspected in every individual with low circulating free T4 (FT4) concentrations
79 (free thyroxine index, FTI, can be a valuable alternative if FT4 determination is not available)
80 associated with low or normal serum TSH. Therefore, CeH represents a major false negative
81 result of the “reflex TSH strategy”, which is a widely accepted method for screening thyroid
82 function by a first-line TSH measurement [4-7]. CeH can significantly affect quality of life at
83 all ages. Therefore, the existence of CeH should always be ruled out in all patients with
84 hypothalamic-pituitary disorders.

85

86 EPIDEMIOLOGY

87 CeH most frequently occurs as a sporadic form of hypothyroidism. It can affect patients
88 of all ages and, despite the recent discovery of X-linked forms of CeH, there is no evidence of
89 a sex predominance. The prevalence of CeH was estimated to range from 1:16,000 to about
90 1:100,000 in the general adult or neonatal populations [4,8-10]. Such variable prevalence

91 probably depends upon several factors, including ethnicity but also differences in sensitivity
92 of the diagnostic strategies.

93

94 **PATHOGENESIS**

95 The mechanisms underlying CeH pathogenesis variably involve both the hypothalamus
96 and pituitary, but they are still undetermined in several cases. Inheritable conditions are the
97 major cause of CeH in newborns and infants (*Table 1*), while gene mutations can also be the
98 underlying cause of CeH with a delayed onset during childhood or even later in life up to
99 adulthood. Expansive lesions of the hypothalamic/pituitary region constitute the major cause
100 of acquired CeH. However, head trauma, vascular accidents, autoimmunity,
101 haemochromatosis or iron overload, and several iatrogenic mechanisms account for a
102 significant number of CeH cases. The causes of CeH are summarized in *Table 2*.

103 The pathological mechanisms accounting for CeH are: a) impaired thyrotrope stimulation or
104 alterations in the thyroid hormone feedback set-point (eg. TRH resistance or *TBLIX*
105 mutations) [11-13]; b) reduced pituitary reserve of thyrotropin (eg. *TSH β* mutations or an
106 insufficient thyrotrope population); c) poor intrinsic biological activity of secreted TSH
107 molecules [14-18].

108

109 **THE PATH**

110 Due to its origin and the whole clinical context, CeH represents a challenging condition in
111 clinical practice. Since no expert consensus or guidance for this condition is currently
112 available, at the end 2016 the European Thyroid Association (ETA) Executive Committee
113 formed a task force to draft the clinical practice guidelines for the diagnosis and management
114 of CeH. A chairperson was identified (L.P.) and seven additional members were selected
115 (G.B., U.F.D., E.F., D.M., N.S., P.v.T.) and subsequently approved by the ETA Guidelines

116 Board and Executive Committee on the basis of their clinical expertise in the field. Three
117 additional experts (M.B., M.D., A.G.), including two of the European Society of Pediatric
118 Endocrinology (ESPE), were selected to give further inputs to the ETA task force. The
119 members of the task force declare no conflict of interest and worked without any financial
120 support. The draft guidance with the panel's recommendations was released at the end of
121 March 2018 and posted in the "members' only" section of the ETA website for 4 weeks to
122 receive comments.

123

124 **EVALUATION SYSTEM AND GRADING FOR RECOMMENDATIONS**

125 A systematic literature review of relevant articles was performed by searching Pubmed, using
126 the terms "central hypothyroidism", "secondary hypothyroidism" and "tertiary
127 hypothyroidism" up to February 2018. Records from personal files and references of relevant
128 articles and textbooks were also included. The task force critically assessed the literature and
129 identified high-quality studies on CeH. The study designs, the quality and consistency of the
130 results, and the statistical analysis used to assess the effects of CeH treatment were carefully
131 considered. It was appreciated that only one randomized controlled trial (RCT) was available
132 and very few reports fulfilled the established criteria. Retrospective studies and expert
133 opinions were also considered. For this reason this document should be considered as an
134 "expert guidance" for clinical endocrinologists. The task force rated the recommendations
135 according to the GRADE system [19,20]. The strength of each statement was classified as
136 strong (1, a recommendation) or weak (2, a suggestion – not a recommendation), depending
137 upon the clinical significance and weight of opinion favouring the statement. Strong
138 recommendations are clinically important best practice and should be applied to most patients
139 in most circumstances. In contrast, weak statements should be considered by the clinician and
140 will be applicable best practice only to certain patients or under certain circumstances. The

141 quality of the literature concerning each aspect of the statement was graded as $\emptyset\emptyset\emptyset\emptyset$ = very
142 low quality (case reports, expert opinion); $\emptyset\emptyset\emptyset\emptyset$ = low quality (case series, case reports,
143 expert opinion); $\emptyset\emptyset\emptyset\emptyset$ = moderate quality (intervention short of RCT or large
144 observational studies), and $\emptyset\emptyset\emptyset\emptyset$ = high quality (RCT evidence/meta-analysis). When
145 appropriate, the level of evidence of some recommendations was upgraded based on studies
146 conducted in primary hypothyroidism. The text and recommendations were then verified
147 according to the AGREE II instrument [21].

148

149 **WHICH PATIENTS ARE AT RISK OF CeH?**

150 The existence of CeH should be suspected in all subjects with a subnormal circulating
151 concentration of FT4 together with an inappropriately low serum TSH. Importantly, thyroid
152 hormone levels change markedly during childhood and adult reference intervals are not
153 universally applicable to children [22]. Therefore, the establishment of the reference interval
154 of TSH and FT4 is critical in the diagnosis of CeH as these values can be affected by age,
155 gender, iodine nutrition, and ethnicity [23]. Manifestations of CeH are similar to those of
156 primary hypothyroidism, but they can be masked by coexistent MPHD [1,24,25]. Therefore,
157 CeH must be suspected and ruled out in all cases with a personal or familial history of
158 hypothalamic-pituitary diseases or with manifestations pointing to a hypothalamic-pituitary
159 lesion. Heritable CeH should also be ruled out in patients with hypothyroid manifestations
160 associated with particular clinical phenotypes such as macro-orchidism, or those with specific
161 neurological manifestations or brain defects on MRI (see Tables 1 & 2, and
162 Recommendations 1-7).

163

164 *Heritable CeH*

165 The number of candidate genes for heritable forms of isolated CeH or CPHDs has
166 recently been expanded thanks to Next Generation Sequencing (NGS). The specific
167 manifestations of candidate gene defects are summarized in *Table 1*.

168 Heritable forms of CeH due to bi-allelic *TSH β* mutations are associated with severe neonatal
169 onset and characterized by the typical manifestations of congenital primary hypothyroidism
170 (eg, jaundice, macroglossia, hoarse cry, failure to thrive and retarded growth, umbilical
171 hernia, hypotonia). If untreated within a few weeks of post-natal life, these patients develop
172 cretinism comparable to patients with severe primary congenital hypothyroidism [26,27].
173 Therefore, CeH must be ruled out in all infants with manifestations of congenital
174 hypothyroidism and inappropriately low TSH concentrations.

175 Defective TRH action due to bi-allelic mutations in the *TRHR* gene has, to date, been
176 described in few families [11,28-30]. Though prolonged neonatal jaundice was reported in
177 one female, even complete TRH resistance does not cause severe neonatal hypothyroidism.
178 The diagnosis in three of the four probands with bi-allelic *TRHR* mutations was made during
179 childhood because of delayed growth accompanied by lethargy and fatigue or by overweight.
180 However, complete TRH resistance was uncovered by genetic testing in one pregnant woman
181 [11]. Blunted TSH and PRL responses to TRH testing suggest *TRHR* involvement [11],
182 though normal responses have also been reported when *TRHR* function is not completely
183 disrupted [30]. Interestingly, heterozygous relatives were reported to have
184 hyperthyrotropinemia in one family [30].

185 Immunoglobulin superfamily member 1 gene (*IGSF1*) defects are the molecular cause of a
186 recently described X-linked syndrome including mild to moderate CeH. In this condition,
187 CeH is associated with abnormal testicular growth leading to adult macro-orchidism (+2.0
188 SDS) but with a tendency towards pubertal delay, low PRL and, rarely, reversible GH

189 deficiency [12,31]. Some female carriers can also manifest CeH. Recent data indicate *IGSF1*
190 as the most frequently implicated gene in congenital CeH [32].

191 Mutations in *TBL1X* are a second cause of X-linked cause of CeH. *TBL1X*, transducin-like
192 protein 1, is an essential subunit of the nuclear receptor corepressor (NCoR)-silencing
193 mediator for retinoid and thyroid hormone receptors (SMRT) complex, the major TH receptor
194 (TR) corepressor (CoR) involved in T3-regulated gene expression. In addition to CeH, many
195 patients exhibit hearing loss [13].

196 Mutations in genes encoding transcription factors that regulate pituitary development are the
197 major cause of heritable MPHDS. In these cases, CeH can be present at birth but can also have
198 a delayed onset. It is associated with an increased mortality risk in newborns [33] and can be
199 associated with variable manifestations, including hypoglycemia, growth and developmental
200 delay, as well as extra-pituitary abnormalities (eg. typical craniofacial or brain MRI defects)
201 (Table 1). The recognition of CeH at neonatal screening and subsequent early diagnosis of
202 congenital MPHD can prevent an impending life-threatening adrenal crisis. The most
203 frequently identified mutations associated with MPHD are in *PROPI*. [27,34-37].

204

205 *Acquired CeH forms*

206 In addition to the classic hypothalamic-pituitary diseases (expansive lesions,
207 hypothalamic or pituitary surgery, cranial irradiation, or inflammatory mechanisms), acquired
208 CeH should be suspected in all patients with moderate to severe head trauma or vascular
209 accident (see *Table 2*). The possibility of evolution of CeH should be ruled out in patients
210 with pituitary lesions after the start of replacement therapies with recombinant human GH
211 (rhGH) or estrogen (see [1]) (Recommendation 8) as well as in those receiving particular
212 drugs (Recommendation 9). In particular, rexinoids (like bexarotene, an agonist of retinoid X
213 receptor that is approved for clinical use, primarily for treatment of cutaneous T cell

214 lymphoma) [38] or mitotane (reported to exert toxic effects on thyrotropes) [39]. Several
215 other drugs (eg, glucocorticoids, anti-epileptics, somatostatin) have transient or controversial
216 TSH suppressive effects [1,38] (see Table 3). The hypothyroid state is mild to moderate in
217 most patients with acquired CeH, as the pituitary TSH reserve is rarely completely depleted
218 [40, 41].

219

220 **HOW CAN CeH BE DIAGNOSED?**

221 The diagnosis of CeH is generally made biochemically by the combined determination of
222 serum TSH and FT4. Overt CeH is most frequently indicated by the combined findings of low
223 FT4 with low or normal TSH concentrations [24,25]. Nevertheless, some CeH patients with a
224 predominant hypothalamic defect can have high serum immunoreactive TSH concentrations,
225 but devoid of full biological activity. In these cases, TSH elevations are similar to those
226 generally found in subclinical or mild primary hypothyroidism and may lead to misdiagnosis
227 [14-17,30,42]. The combination of low FT4 and inappropriately low TSH should be
228 confirmed on two separate determinations and after the exclusion of several conditions that
229 could lead to misdiagnosis and are listed in *Table 3*. In particular, the isolated finding of low
230 FT3 is indicative of non-thyroidal illnesses or deiodinase defects, rather than CeH.

231 In the absence of any technical problem or interference, the finding of low FT4 combined
232 with an inappropriately low or normal TSH accurately delineates the diagnosis of overt forms
233 of CeH, but the diagnosis of milder defects, characterized by FT4 concentrations still within
234 the normal range (mild or hidden CeH), remains problematic. Since mild hypothyroidism can
235 be associated with a reduced physical performance and metabolic consequences, as well as
236 with a decreased growth velocity in children, several additional determinations can be useful
237 to support the diagnosis of patients with mild CeH (borderline low FT4) [1,43-45] (*Table 4*).

238 In particular, in patients under follow-up for hypothalamic/pituitary disease, the diagnosis of

239 mild forms of CeH should be considered when serum FT4 decreases from higher values into
240 the lower quartile of the normal range, in particular when a FT4 decrease >20% of previous
241 values is seen despite a low or normal TSH (provided that the indices are measured in the
242 same laboratory and by the same assay) [25]. In such context, an English group proposed the
243 calculation of a TSH index (TSHI) based on the physiological log-linear relationship between
244 circulating FT4 and TSH concentrations in a large reference population [46], and more
245 recently a Brazilian group proposed the determination of echocardiographic parameters [47].
246 The relative application of the tests and findings reported in Table 4 depends upon the
247 different settings and local regulations. (Recommendations 10-14). The determination of the
248 ratio between biological and immunological activity of circulating TSH in experimental
249 biological assays may also be of diagnostic support in certain cases [14-18].
250 In addition, the task force agreed that a trial of thyroxine treatment over three months may be
251 considered to verify its beneficial effects and to support the diagnosis of a mild form of CeH
252 (borderline low FT4) in patients with otherwise unexplained hypothyroid manifestations.

253

254 **WHEN AND HOW SHOULD GENETIC ANALYSES BE PERFORMED?**

255

256 Genetic analyses should be performed in congenital or familial cases and in cases of CeH
257 onset during childhood or at any age when the condition remains unexplained. Genetic testing
258 can also support the diagnosis of idiopathic mild forms of CeH (borderline low FT4). In index
259 cases, genetic analyses should be performed by direct sequencing following a phenotype-
260 driven approach or by NGS using a panel of candidate genes [36,48](see *Table 1*).
261 Importantly, Whole Exome or Genome Sequencing (WES or WGS) and/or Comparative
262 Genomic Hybridization (CGH) array can be considered in sporadic or familial cases of CeH
263 with negative candidate gene analyses. When causative mutations in candidate genes are

264 found, the genetic analyses should be extended to all first-degree relatives for CeH diagnosis
265 or to uncover the carrier status (Recommendations 15-18).

266

267 **HOW SHOULD CeH PATIENTS BE MANAGED AND TREATED?**

268 Whenever a diagnosis of CeH is confirmed, replacement treatment can be started only
269 after obtaining evidence of conserved cortisol secretion or under proper hydrocortisone
270 replacement. Thus, if coexistent central adrenal insufficiency cannot be ruled out or is not yet
271 treated, thyroid replacement must be started after steroid therapy in order to prevent the
272 possible precipitation of an adrenal crisis, and the assessment of corticotrope function can be
273 postponed (recommendation 19). However, replacement with thyroid hormone should not be
274 delayed in newborns and infants with symptomatic CeH.

275 Treatment of CeH should restore appropriate serum concentrations of thyroid hormones.
276 Since the only trial comparing standard L-T4 and L-T4 + L-T3 combination therapy in CeH
277 did not prove a superior efficacy of the combination [49], it is recommended that L-T4
278 monotherapy remains the standard treatment for hypothyroidism (Recommendation 20), in
279 accord with the American Thyroid Association guidelines [50]. L-T4 + L-T3 combination
280 therapy might be considered as an experimental approach in compliant L-T4-treated
281 hypothyroid patients who have persistent complaints despite adequate FT4 concentrations,
282 following the ETA guidance [51]. However, in CeH where TSH is an unreliable monitor of
283 thyroid hormone status, the risk of overtreatment by this approach is far higher than in
284 primary hypothyroidism [49].

285 In children and young adults, a starting full replacement dose of L-T4 can generally be
286 advised when commencing treatment. In congenital CeH, high L-T4 treatment should be
287 started as soon as possible (optimally within 2 weeks after birth) at doses used also for
288 primary congenital hypothyroidism (10-12 $\mu\text{g}/\text{kg}$ body weight (bw)/day), in order to rapidly

289 rescue serum FT4 concentrations to normal range and secure optimal neurodevelopment as
290 soon as possible [52]. In milder congenital forms of CeH, commencement of treatment with
291 lower LT4 doses (5-10 $\mu\text{g}/\text{kg}$ bw/day) can also be considered and should avoid the risk of
292 overtreatment (recommendations 21, 22).

293 As in primary hypothyroidism [53], younger CeH patients require higher doses than the
294 older ones [24,25]. In children, L-T4 treatment was reported to promote an acceleration of
295 growth velocity allowing attainment of target height [11,28,43]. Progressively lower doses are
296 required in the transition to adulthood [54]. Indeed, mean L-T4 daily doses of 1.2-1.6 $\mu\text{g}/\text{kg}$
297 bw/day were judged sufficient in the large majority of adult CeH patients, with the main aim
298 of achieving a more appropriate metabolic profile [24,25,55]. In the elderly or in patients with
299 long-standing hypothyroidism that are at risk of untoward effects mainly due to concomitant
300 heart diseases, L-T4 treatment could be started at a lower daily dosage and then progressively
301 increased during the following weeks or months up to 1.0-1.2 $\mu\text{g}/\text{kg}$ bw/day
302 (Recommendations 23, 24). Treatment of milder forms of CeH (FT4 concentrations within
303 the lower limit of normal range) may be dispensable in elderly patients >75 years of age
304 (Recommendation 25).

305 The determination of circulating free thyroid hormone concentrations is of major
306 significance in monitoring L-T4 treatment in CeH patients [1,24,25,49,56-58]. Blood should
307 be withdrawn before or at least 4 hours after the L-T4 administration [59]. The determination
308 of FT4 acquires a more relevant role in the evaluation of replacement therapy than in primary
309 hypothyroidism. Several groups [49,56,58,60] reported that concentrations of FT4 in the
310 upper part of normal range might represent an appropriate target in most treated CeH patients
311 (Recommendation 26).

312 In primary hypothyroidism, L-T4 replacement is easily tuned by serum TSH
313 measurement, but this parameter has a different significance in CeH patients. In particular,

314 serum TSH concentrations are rapidly suppressed in a large portion of CeH patients during
315 the administration of L-T4 [24,25]. A couple of groups also reported that low TSH values are
316 more likely to be associated with adequate replacement in CeH patients [61,62]. Therefore, a
317 TSH value above the lower limit of normal may indicate the need for up-titrating the daily L-
318 T4 dose. However, the TSH determination becomes useless during treatment of CeH in
319 patients with low baseline concentrations of TSH. (Recommendations 27).

320 Once adequate thyroid replacement is achieved, paediatric patients with CeH should
321 undergo monitoring of FT4 according to the age-related reference ranges and should be
322 monitored like patients with primary hypothyroidism. An annual monitoring of FT4 should be
323 sufficient in adult CeH patients. The experts recommend that TSH or T3 should be measured
324 only when insufficient or excessive replacement, respectively, is suspected
325 (Recommendations 28-30).

326 On the basis of previously illustrated recommendations, an insufficient replacement should be
327 suspected in CeH patients with serum FT4 concentrations below or close to the lower limit of
328 the normal range, in particular if associated with serum TSH >1.0 mU/L and multiple and
329 persistent hypothyroid manifestations (Recommendation 31). Several conditions are
330 associated with increased thyroid hormone requirements through different mechanisms. In
331 comparison with primary hypothyroidism, there is a higher frequency for such conditions
332 because of the persistent impact from recombinant human growth hormone (rhGH) (reviewed
333 in [63]). Estrogen therapy is also known to impact on thyroid replacement, and this is even
334 more so when medically-assisted fertility treatments are used [64], but these effects are
335 generally transient in most patients [25,65]. During pregnancy, a 25-50% increase of the L-T4
336 dose is advised and it is probably better to aim at a higher fT4 concentration, in the upper
337 quartile of the normal range, to minimize the risk of thyroid hormone underreplacement for

338 the fetus [50]. In summary, an up-titration of L-T4 therapy should be considered in all
 339 conditions listed in Recommendation 32.

340 In contrast, as in the case of primary hypothyroidism, down-titration of the L-T4 dose
 341 should be considered in elderly CeH patients, in particular if associated with cardiovascular
 342 morbidities, and after parturition or menopause, or when the concomitant treatments listed in
 343 “Recommendation 31” are withdrawn (Recommendation 33). The L-T4 overtreatment should
 344 be considered in CeH patients with serum FT4 values above or close to the upper limit of
 345 normal (provided that the daily L-T4 dose is taken after blood withdrawal), in particular if
 346 associated with clinical thyrotoxic manifestations, or high T3 concentrations
 347 (Recommendation 34).

348

349 **References**

- 350 **1.** Persani L: Clinical review: Central hypothyroidism: pathogenic, diagnostic, and
 351 therapeutic challenges. *J Clin Endocrinol Metab* 2012; 97:3068-3078
- 352 **2.** Persani L, Beck-Peccoz P: Central Hypothyroidism. In: Braverman LE, Cooper D, ed.
 353 Werner & Ingbar’s *The Thyroid: a fundamental and clinical text*. 10th ed. Lippincott Williams
 354 & Wilkins/Wolters Kluwert Health, Philadelphia, 2012:560-568.
- 355 **3.** Zwaveling-Soonawala N, van Trotsenburg AS, Verkerk PH: The severity of
 356 congenital hypothyroidism of central origin should not be underestimated. *J Clin Endocrinol*
 357 *Metab* 2015; 100:E297-300
- 358 **4.** Price A, Weetman AP: Screening for central hypothyroidism is unjustified. *Br Med J*
 359 2001; 322:798
- 360 **5.** Baloch Z, Carayon P, Conte-Devolx B, Demers LM, Feldt-Rasmussen U, Henry JF,
 361 LiVosli VA, Niccoli-Sire P, John R, Ruf J, Smyth PP, Spencer CA, Stockigt JR: Laboratory
 362 medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid
 363 disease. *Thyroid* 2003; 13:3-126
- 364 **6.** Wardle CA, Fraser WD, Squire CR: Pitfalls in the use of thyrotropin concentration as
 365 a first-line thyroid-function test. *Lancet* 2001; 357:1013-1014
- 366 **7.** Baquedano MS, Ciaccio M, Dujovne N, Herzovich V, Longueira Y, Warman DM,
 367 Rivarola MA, Belgorosky A: Two novel mutations of the TSH-beta subunit gene underlying
 368 congenital central hypothyroidism undetectable in neonatal TSH screening. *J Clin Endocrinol*
 369 *Metab* 2010; 95:E98-103
- 370 **8.** Kempers MJ, van der Sluijs Veer L, Nijhuis-van der Sanden RW, Lanting CI, Kooistra
 371 L, Wiedijk BM, Last BF, de Vijlder JJ, Grootenhuis MA, Vulsma T: Neonatal screening for
 372 congenital hypothyroidism in the Netherlands: cognitive and motor outcome at 10 years of
 373 age. *J Clin Endocrinol Metab* 2007; 92:919-924
- 374 **9.** Nebesio TD, McKenna MP, Nabhan ZM, Eugster EA: Newborn screening results in
 375 children with central hypothyroidism. *J Pediatrics* 2010; 156:990-993

- 376 **10.** Adachi M, Soneda A, Asakura Y, Muroya K, Yamagami Y, Hirahara F: Mass
377 screening of newborns for congenital hypothyroidism of central origin by free thyroxine
378 measurement of blood samples on filter paper. *Eur J Endocrinol* 2012; 166:829-838
- 379 **11.** Bonomi M, Busnelli M, Beck-Peccoz P, Costanzo D, Antonica F, Dolci C, Pilotta A,
380 Buzi F, Persani L: A family with complete resistance to thyrotropin-releasing hormone. *N*
381 *Engl J Med* 2009; 360:731-734
- 382 **12.** Sun Y, Bak B, Schoenmakers N, van Trotsenburg AS, Oostdijk W, Voshol P,
383 Cambridge E, White JK, le Tissier P, Gharavy SN, Martinez-Barbera JP, Stokvis-Brantsma
384 WH, Vulsma T, Kempers MJ, Persani L, Campi I, Bonomi M, Beck-Peccoz P, Zhu H, Davis
385 TM, Hokken-Koelega AC, Del Blanco DG, Rangesami JJ, Ruivenkamp CA, Laros JF, Kriek
386 M, Kant SG, Bosch CA, Biermasz NR, Appelman-Dijkstra NM, Corssmit EP, Hovens GC,
387 Pereira AM, den Dunnen JT, Wade MG, Breuning MH, Hennekam RC, Chatterjee K, Dattani
388 MT, Wit JM, Bernard DJ: Loss-of-function mutations in IGSF1 cause an X-linked syndrome
389 of central hypothyroidism and testicular enlargement. *Nat Genet* 2012; 44:1375-1381
- 390 **13.** Heinen CA, Losekoot M, Sun Y, Watson PJ, Fairall L, Joustra SD, Zwaveling-
391 Soonawala N, Oostdijk W, van den Akker EL, Alders M, Santen GW, van Rijn RR, Dreschler
392 WA, Surovtseva OV, Biermasz NR, Hennekam RC, Wit JM, Schwabe JW, Boelen A, Fliers
393 E, van Trotsenburg AS: Mutations in TBL1X Are Associated With Central Hypothyroidism. *J*
394 *Clin Endocrinol Metab* 2016; 101:4564-4573
- 395 **14.** Faglia G, Bitensky L, Pinchera A, Ferrari C, Paracchi A, Beck-Peccoz P, Ambrosi B,
396 Spada A: Thyrotropin secretion in patients with central hypothyroidism: evidence for reduced
397 biological activity of immunoreactive thyrotropin. *J Clin Endocrinol Metab* 1979; 48:989-998
- 398 **15.** Beck-Peccoz P, Amr S, Menezes-Ferreira MM, Faglia G, Weintraub BD: Decreased
399 receptor binding of biologically inactive thyrotropin in central hypothyroidism. Effect of
400 treatment with thyrotropin-releasing hormone. *N Engl J Med* 1985; 312:1085-1090
- 401 **16.** Horimoto M, Nishikawa M, Ishihara T, Yoshikawa N, Yoshimura M, Inada M:
402 Bioactivity of thyrotropin (TSH) in patients with central hypothyroidism: comparison
403 between in vivo 3,5,3'-triiodothyronine response to TSH and in vitro bioactivity of TSH. *J*
404 *Clin Endocrinol Metab* 1995; 80:1124-1128
- 405 **17.** Persani L, Ferretti E, Borgato S, Faglia G, Beck-Peccoz P: Circulating thyrotropin
406 bioactivity in sporadic central hypothyroidism. *J Clin Endocrinol Metab* 2000; 85:3631-3635
- 407 **18.** Persani L, Tonacchera M, Beck-Peccoz P, Vitti P, Mammoli C, Chiovato L, Elisei R,
408 Faglia G, Ludgate M, Vassart G: Measurement of cAMP accumulation in Chinese hamster
409 ovary cells transfected with the recombinant human TSH receptor (CHO-R): a new bioassay
410 for human thyrotropin. *J Endocrinol Invest* 1993; 16:511-519
- 411 **19.** Guyatt GH, Oxman AD, Vist GE, et al: GRADE Working Group: GRADE: an
412 emerging consensus on rating quality of evidence and strength of recommendations. *Br Med J*
413 2008; 336: 924-926.
- 414 **20.** Swiglo BA, Murad MH, Schunemann HJ, Kunz R, Vigersky RA, Guyatt GH, Montori
415 VM: A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice
416 guidelines in endocrinology using the grading of recommendations, assessment, development,
417 and evaluation system. *J Clin Endocrinol Metab* 2008; 93: 666-673.
- 418 **21.** Brouwers MC, Kho ME, Browman GP, et al. AGREE II: Advancing guideline
419 development, reporting and evaluation in healthcare. *CMAJ* 2010;182:E839-842.
- 420 **22.** Kapelari K, Kirchlechner C, Högl W, Schweitzer K, Virgolini I, Moncayo R:
421 Pediatric reference intervals for thyroid hormone levels from birth to adulthood: a
422 retrospective study. *BMC Endocr Disord.* 2008; 8:15.
- 423 **23.** Park SY, Kim HI, Oh HK, Kim TH, Jang HW, Chung JH, Shin MH, Kim SW: Age-
424 and gender-specific reference intervals of TSH and free T4 in an iodine-replete area: Data

- 425 from Korean National Health and Nutrition Examination Survey IV (2013-2015). *PLoS One*.
426 2018; 13:e0190738.
- 427 **24.** Ferretti E, Persani L, Jaffrain-Rea ML, Giambona S, Tamburrano G, Beck-Peccoz P:
428 Evaluation of the adequacy of levothyroxine replacement therapy in patients with central
429 hypothyroidism. *J Clin Endocrinol Metab* 1999; 84:924-929
- 430 **25.** Alexopoulou O, Beguin C, De Nayer P, Maiter D: Clinical and hormonal
431 characteristics of central hypothyroidism at diagnosis and during follow-up in adult patients.
432 *Eur J Endocrinol* 2004; 150:1-8
- 433 **26.** Bonomi M, Proverbio MC, Weber G, Chiumello G, Beck-Peccoz P, Persani L:
434 Hyperplastic pituitary gland, high serum glycoprotein hormone alpha-subunit, and variable
435 circulating thyrotropin (TSH) levels as hallmark of central hypothyroidism due to mutations
436 of the TSH beta gene. *J Clin Endocrinol Metab* 2001; 86:1600-1604
- 437 **27.** Miyai K: Congenital thyrotropin deficiency--from discovery to molecular biology,
438 postgenome and preventive medicine. *Endocrine J* 2007; 54:191-203
- 439 **28.** Collu R, Tang J, Castagne J, Lagace G, Masson N, Huot C, Deal C, Delvin E,
440 Faccenda E, Eidne KA, Van Vliet G: A novel mechanism for isolated central hypothyroidism:
441 inactivating mutations in the thyrotropin-releasing hormone receptor gene. *J Clin Endocrinol*
442 *Metab* 1997; 82:1561-1565
- 443 **29.** Koulouri O, Nicholas AK, Schoenmakers E, Mokrosinski J, Lane F, Cole T, Kirk J,
444 Farooqi IS, Chatterjee VK, Gurnell M, Schoenmakers N: A Novel Thyrotropin-Releasing
445 Hormone Receptor Missense Mutation (P81R) in Central Congenital Hypothyroidism. *J Clin*
446 *Endocrinol Metab* 2016; 101:847-851
- 447 **30.** Garcia M, Gonzalez de Buitrago J, Jimenez-Roses M, Pardo L, Hinkle PM, Moreno
448 JC: Central Hypothyroidism Due to a TRHR Mutation Causing Impaired Ligand Affinity and
449 Transactivation of Gq. *J Clin Endocrinol Metab* 2017; 102:2433-2442
- 450 **31.** Joustra SD, van der Plas EM, Goede J, Oostdijk W, Delemarre-van de Waal HA, Hack
451 WW, van Buuren S, Wit JM. New reference charts for testicular volume in Dutch children
452 and adolescents allow the calculation of standard deviation scores. *Acta Paediatr* 2015;
453 104:e271-278.
- 454 **32.** Joustra SD, Heinen CA, Schoenmakers N, Bonomi M, Ballieux BE, Turgeon MO,
455 Bernard DJ, Fliers E, van Trotsenburg AS, Losekoot M, Persani L, Wit JM, Biermasz NR,
456 Pereira AM, Oostdijk W: IGSF1 Deficiency: Lessons From an Extensive Case Series and
457 Recommendations for Clinical Management. *J Clin Endocrinol Metab* 2016; 101:1627-1636
- 458 **33.** Zwaveling-Soonawala N, Naafs JC, Verkerk PH, van Trotsenburg ASP. Mortality in
459 children with early detected congenital central hypothyroidism. *J Clin Endocrinol Metab*.
460 2018 [Epub ahead of print]
- 461 **34.** Yamada M, Mori M: Mechanisms related to the pathophysiology and management of
462 central hypothyroidism. *Nat Clin Pract Endocrinol Metab* 2008; 4:683-694
- 463 **35.** Pfaffle R, Klammt J: Pituitary transcription factors in the aetiology of combined
464 pituitary hormone deficiency. *Best Pract Res Clin Endocrinol Metab* 2011; 25:43-60
- 465 **36.** Persani L, Bonomi M: The multiple genetic causes of central hypothyroidism. *Best*
466 *Pract Res Clin Endocrinol Metab* 2017; 31:255-263
- 467 **37.** Giri D, Vignola ML, Gualtieri A, Scagliotti V, McNamara P, Peak M, Didi M,
468 Gaston-Massuet C, Senniappan S: Novel FOXA2 mutation causes Hyperinsulinism,
469 Hypopituitarism with craniofacial and endoderm-derived organ abnormalities. *Hum Mol*
470 *Genet* 2017; 26:4315-4326
- 471 **38.** Haugen BR. Drugs that suppress TSH or cause central hypothyroidism. *Best Pract Res*
472 *Clin Endocrinol Metab* 2009; 23:793-800

- 473 **39.** Russo M, Scollo C, Pellegriti G, Cotta OR, Squatrito S, Frasca F, Cannavò S, Gullo D.
474 Mitotane treatment in patients with adrenocortical cancer causes central hypothyroidism. *Clin*
475 *Endocrinol (Oxf)*. 2016;84:614-6199.
- 476 **40.** Neumann S, Raaka BM, Gershengorn MC: Constitutively active thyrotropin and
477 thyrotropin-releasing hormone receptors and their inverse agonists. *Methods Enzymol* 2010;
478 485:147-160
- 479 **41.** Barbesino G, Sluss PM, Caturegli P: Central hypothyroidism in a patient with pituitary
480 autoimmunity: evidence for TSH-independent thyroid hormone synthesis. *J Clin Endocrinol*
481 *Metab* 2012; 97:345-350
- 482 **42.** Lee KO, Persani L, Tan M, Sundram FX, Beck-Peccoz P: Thyrotropin with decreased
483 biological activity, a delayed consequence of cranial irradiation for nasopharyngeal
484 carcinoma. *J Endocrinol Invest* 1995; 18:800-805
- 485 **43.** Rose SR: Cranial irradiation and central hypothyroidism. *Trends Endocrinol Metab*
486 2001; 12:97-104
- 487 **44.** Rose SR, Lustig RH, Pitukcheewanont P, Broome DC, Burghen GA, Li H, Hudson
488 MM, Kun LE, Heideman RL: Diagnosis of hidden central hypothyroidism in survivors of
489 childhood cancer. *J Clin Endocrinol Metab* 1999; 84:4472-4479
- 490 **45.** Darzy KH, Shalet SM: Circadian and stimulated thyrotropin secretion in cranially
491 irradiated adult cancer survivors. *J Clin Endocrinol Metab* 2005; 90:6490-6497
- 492 **46.** Jostel A, Ryder WD, Shalet SM. The use of thyroid function tests in the diagnosis of
493 hypopituitarism: definition and evaluation of the TSH Index. *Clin Endocrinol (Oxf)*. 2009;
494 71:529-534.
- 495 **47.** Doin FC, Rosa-Borges M, Martins MR, Moisés VA, Abucham J. Diagnosis of
496 subclinical central hypothyroidism in patients with hypothalamic-pituitary disease by Doppler
497 echocardiography. *Eur J Endocrinol*. 2012;166:631-640
- 498 **48.** Persani L, de Filippis T, Colombo C, Gentilini D. Genetics In Endocrinology: Genetic
499 diagnosis of endocrine diseases by NGS: novel scenarios and unpredictable risks. *Eur J*
500 *Endocrinol*. 2018 [Epub ahead of print]
- 501 **49.** Slawik M, Klawitter B, Meiser E, Schories M, Zwermann O, Borm K, Peper M,
502 Lubrich B, Hug MJ, Nauck M, Olschewski M, Beuschlein F, Reincke M: Thyroid hormone
503 replacement for central hypothyroidism: a randomized controlled trial comparing two doses
504 of thyroxine (T4) with a combination of T4 and triiodothyronine. *J Clin Endocrinol Metab*
505 2007; 92:4115-4122
- 506 **50.** Jonklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola, AR, Celi FS, Cooper DS,
507 Kim BW, Peeters RP, Rosenthal MS, Sawka AM: Guidelines for the treatment of
508 hypothyroidism. *Thyroid* 2014; 24:1670-1751
- 509 **51.** Wiersinga WM, Duntas L, Fadeyev V, Nygaard B, Vanderpump MP: 2012 ETA
510 Guidelines: The Use of L-T4 + L-T3 in the Treatment of Hypothyroidism. *Eur Thyroid J*
511 2012; 1:55-71
- 512 **52.** Aleksander P, Bruckner-Spieler M, Stohr AM, Lankes E, Kuhnen P, Schnabel D,
513 Ernert A, Stablein W, Craig ME, Blankenstein O, Gruters A, Krude H: Mean high dose L-
514 thyroxine treatment is efficient and safe to achieve a normal IQ in young adult patients with
515 congenital hypothyroidism. *J Clin Endocrinol Metab* 2018;
- 516 **53.** Helfand M, Crapo LM: Monitoring therapy in patients taking levothyroxine. *Ann Int*
517 *Med* 1990; 113:450-454
- 518 **54.** Koch CA, Sarlis NJ: The spectrum of thyroid diseases in childhood and its evolution
519 during transition to adulthood: natural history, diagnosis, differential diagnosis and
520 management. *J Endocrinol Invest* 2001; 24:659-675
- 521 **55.** Feldt-Rasmussen U, Klohe M: Central hypothyroidism and its role for cardiovascular
522 risk factors in hypopituitary patients. *Endocrine* 2016; 54:15-23

- 523 **56.** Iverson JF, Mariash CN: Optimal free thyroxine levels for thyroid hormone
524 replacement in hypothyroidism. *Endocrine Pract* 2008; 14:550-555
- 525 **57.** Beck-Peccoz P: Treatment of central hypothyroidism. *Clin Endocrinol* 2011; 74:671-
526 672
- 527 **58.** Koulouri O, Auldin MA, Agarwal R, Kieffer V, Robertson C, Falconer Smith J, Levy
528 MJ, Howlett TA: Diagnosis and treatment of hypothyroidism in TSH deficiency compared to
529 primary thyroid disease: pituitary patients are at risk of under-replacement with
530 levothyroxine. *Clin Endocrinol* 2011; 74:744-749
- 531 **59.** Leger J, Olivieri A, Donaldson M, Torresani T, Krude H, van Vliet G, Polak M, Butler
532 G: European Society for Paediatric Endocrinology consensus guidelines on screening,
533 diagnosis, and management of congenital hypothyroidism. *Horm Res Ped* 2014; 81:80-103
- 534 **60.** Hirata Y, Fukuoka H, Iguchi G, Iwahashi Y, Fujita Y, Hari Y, Iga M, Nakajima S,
535 Nishimoto Y, Mukai M, Hirota Y, Sakaguchi K, Ogawa W, Takahashi Y: Median-lower
536 normal levels of serum thyroxine are associated with low triiodothyronine levels and body
537 temperature in patients with central hypothyroidism. *Eur J Endocrinol* 2015; 173:247-256
- 538 **61.** Carrozza V, Csako G, Yanovski JA, Skarulis MC, Nieman L, Wesley R, Pucino F:
539 Levothyroxine replacement therapy in central hypothyroidism: a practice report.
540 *Pharmacotherapy* 1999; 19:349-355
- 541 **62.** Shimon I, Cohen O, Lubetsky A, Olchovsky D: Thyrotropin suppression by thyroid
542 hormone replacement is correlated with thyroxine level normalization in central
543 hypothyroidism. *Thyroid* 2002; 12:823-827
- 544 **63.** Beck-Peccoz P, Rodari G, Giavoli C, Lania A. Central hypothyroidism - a neglected
545 thyroid disorder. *Nat Rev Endocrinol.* 2017; 13:588-598.
- 546 **64.** Benaglia L, Busnelli A, Somigliana E, Leonardi M, Vannucchi G, De Leo S,
547 Fugazzola L, Ragni G, Fedele L: Incidence of elevation of serum thyroid-stimulating
548 hormone during controlled ovarian hyperstimulation for in vitro fertilization. *Eur J Obst*
549 *Gynecol Reprod Biol* 2014; 173:53-57
- 550 **65.** Arafah BM: Increased need for thyroxine in women with hypothyroidism during
551 estrogen therapy. *N Engl J Med* 2001; 344:1743-1749
- 552

554 **RECOMMENDATIONS**555 * **Recommendations for pediatric subjects**556 ^ **Recommendations for adult subjects**557 **WHICH PATIENTS ARE AT RISK OF CeH?****Recommendation 1*^**

We recommend that the diagnosis of CeH should be considered in every subject with low serum concentrations of FT4 and low or normal TSH on a screening examination.

Strength of recommendation: 1; Level of evidence: ØØØØ

558

Recommendation 2*

We recommend that the diagnosis of CeH should be considered in neonates and children with clinical manifestations of congenital hypothyroidism, but low or normal neonatal TSH screening.

Strength of recommendation: 1; Level of evidence: ØØØØ

559

Recommendation 3*^

We suggest that the diagnosis of CeH should be considered in patients with a low serum concentration of FT4 and slight TSH elevations (<10 mU/L, or inappropriately lower than expected on the basis of the hypothyroid state).

Strength of recommendation: 2; Level of evidence: ØØØØ

560

Recommendation 4*

We recommend screening for CeH all children with a familial history of CeH and/or failure to thrive, developmental delay, GH deficiency, delayed or precocious puberty or other hypothalamic-pituitary defects or lesions.

Strength of recommendation: 1; Level of evidence: ØØØØ

561

Recommendation 5*^

We recommend that CeH due to *IGSF1* defect should be ruled out in adolescents or adult patients with macroorchidism.

Strength of recommendation: 1; Level of evidence: ØØØØ

562

Recommendation 6*^

We recommend screening for CeH all patients with personal or familial history of hypothalamic-pituitary lesions or diseases, moderate to severe head trauma, stroke, previous cranial irradiation, haemochromatosis or iron overload, in particular when hypothyroid manifestations are present.

Strength of recommendation: 1; Level of evidence: ØØØØ

563

Recommendation 7*^

We recommend screening for CeH all patients with hypothyroid manifestations associated with clinical findings pointing to a hypothalamic-pituitary disease (eg, hyperprolactinaemia, acromegalic features, diabetes insipidus, recurrent headaches, visual field defects), newborns with hypotonia and/or prolonged jaundice, and/or signs of congenital hypopituitarism (eg,

micropenis with undescended testes), as well as children with developmental delay.

Strength of recommendation: 1; Level of evidence: ØØØØ

564

Recommendation 8*^

We recommend that the onset of CeH should be evaluated in patients with hypothalamic/pituitary disease after the start of treatment with rhGH or estrogen.

Strength of recommendation: 1; Level of evidence: ØØØØ

565

Recommendation 9*^

We recommend that the onset of CeH should be evaluated in patients on treatments with ligands of the retinoid X receptor (RXR), ipilimumab (or other check-point inhibitors) or mitotane.

Strength of recommendation: 1; Level of evidence: ØØØØ

566

HOW SHOULD CeH BE DIAGNOSED?

Recommendation 10*^

We recommend the combined determination of serum FT4 and TSH in order to evaluate the presence of CeH.

Strength of recommendation: 1; Level of evidence: ØØØØ

568

Recommendation 11*^

We recommend that CeH diagnosis should be confirmed by the combined findings of serum FT4 concentrations below the lower limit of the normal range and inappropriately low/normal TSH concentrations on at least two separate determinations, and after exclusion of the conditions reported in Table 3.

Strength of recommendation: 1; Level of evidence: ØØØØ

569

Recommendation 12*^

The isolated finding of low FT3 or total T3 concentrations is not indicative of CeH, but rather of non-thyroidal illness or deiodination defects (e.g. *SBP2* gene defect).

Strength of recommendation: 1; Level of evidence: ØØØØ

570

Recommendation 13*^

In patients under follow-up for hypothalamic-pituitary disease, FT4 and TSH should be monitored during childhood at least bi-annually and later on a yearly basis, and we suggest that CeH diagnosis should be considered when serum FT4 falls in the lower quartile of the normal range, in particular when a FT4 decrease >20% of previous values is seen (provided that the variables are measured by the same assay) despite a low or normal TSH.

Strength of recommendation: 2; Level of evidence: ØØØØ

571

Recommendation 14*^

We suggest that the diagnosis of mild CeH (borderline low FT4, with inappropriately low TSH) should be supported by a combination of several other findings summarized in table 4 (the relative application and importance of these tests and findings may vary in different settings).

Strength of recommendation: 2; Level of evidence: ØØØØ

572

WHEN AND HOW SHOULD GENETIC ANALYSES BE PERFORMED?

573

Recommendation 15*[^]

We recommend genetic analyses in congenital cases and in cases of CeH onset during childhood or at any age when CeH remains unexplained or to support the diagnosis of idiopathic mild forms of CeH (borderline low FT4).

Strength of recommendation: 1; Level of evidence: ØØØØ

574

Recommendation 16*[^]

In index cases, we recommend genetic analyses by direct sequencing following a phenotype-driven approach or by NGS using a panel of candidate genes*.

Strength of recommendation: 1; Level of evidence: ØØØØ

575

**(see Table 1)*

576

Recommendation 17*[^]

We suggest that WES/WGS/CGH array should be considered in sporadic or familial cases of CeH with negative candidate gene analyses.

Strength of recommendation: 2; Level of evidence: ØØØØ

577

Recommendation 18*[^]

When causative mutations in candidate genes are found, we recommend the extension of the genetic analyses to all first-degree relatives for (early) CeH diagnosis or to uncover the carrier status.

Strength of recommendation: 1; Level of evidence: ØØØØ

578

579

HOW SHOULD CeH PATIENTS BE MANAGED AND TREATED?**Recommendation 19*[^]**

We recommend levothyroxine (L-T4) as first line treatment of CeH.

Strength of recommendation: 1; Level of evidence: ØØØØ

580

Recommendation 20*[^]

In CeH patients, we recommend starting replacement treatment with levothyroxine (L-T4) only after evidence of conserved cortisol secretion. If coexistent central adrenal insufficiency is not ruled out, thyroid replacement must be started after steroid therapy in order to prevent the possible induction of an adrenal crisis.

Strength of recommendation: 1; Level of evidence: ØØØØ

581

Recommendation 21*

In congenital and severe forms of CeH (eg, TSH β mutations), we recommend starting L-T4 treatment as soon as possible (optimally within 2 weeks after birth) at doses used also for primary congenital hypothyroidism (10-12 $\mu\text{g}/\text{kg}$ bw/day), in order to rapidly rescue serum FT4 levels to normal range and secure optimal treatment as quickly as possible.

Strength of recommendation: 1; Level of evidence: ØØØØ

582

Recommendation 22*

In milder forms of congenital CeH, we suggest to start replacement therapy at lower LT4 doses (5-10 $\mu\text{g}/\text{kg}$ bw/day), to avoid the risk of overtreatment.

Strength of recommendation: 2; Level of evidence: ØØØØ

583

Recommendation 23*

In CeH forms diagnosed during childhood or adolescence, we recommend to start L-T4

treatment at doses of 3.0-5.0 or 2.0-2.4 µg/kg bw/day, respectively.

Strength of recommendation: 1; Level of evidence: ØØØØ

584

Recommendation 24[^]

In adult patients with CeH, we recommend targeting of L-T4 replacement to a dose according to age and body weight:

- 1.21-1.6 µg/kg bw/day in patients younger than 60 years of age
- 1.0-1.2 µg/kg bw/day in adults older than 60 years of age, or in younger patients with concomitant cardiac disease

Strength of recommendation: 1; Level of evidence: ØØØØ

585

Recommendation 25[^]

As in primary disease, we recommend to avoid treatment of milder forms of CeH (FT4 concentrations within the lower limit of normal range) in elderly patients >75 years of age.

Strength of recommendation: 1; Level of evidence: ØØØØ

Recommendation 26*[^]

In patients with CeH, we recommend to check adequacy of replacement therapy 6-8 weeks after the start of L-T4 replacement with concomitant FT4 and TSH measurements, provided that blood is withdrawn before the morning replacement dose or at least 4 hours after the L-T4 administration. We recommend that replacement therapy should be aimed to maintain FT4 above the median value of the normal range.

Strength of recommendation: 1; Level of evidence: ØØØØ

586

Recommendation 27*[^]

Low TSH concentrations in serum point to an adequate replacement in CeH patients with TSH values above the lower limit of normal range at baseline. The TSH determination becomes useless during treatment of CeH cases with low TSH values at baseline.

Strength of recommendation: 1; Level of evidence: ØØØØ

587

Recommendation 28*

Once adequate thyroid replacement is achieved, we recommend monitoring paediatric patients with CeH by maintaining FT4 concentrations according to the age-related reference ranges and their follow-up should be conducted like in patients with primary hypothyroidism.

Strength of recommendation: 1; Level of evidence: ØØØØ

588

Recommendation 29[^]

Once adequate thyroid replacement is achieved, we recommend annual monitoring of FT4 in adult patients with CeH.

Strength of recommendation: 1; Level of evidence: ØØØØ

589

Recommendation 30*[^]

We recommend that TSH and/or T3 (total or free) should be measured in CeH patients when insufficient or excessive replacement is suspected.

Strength of recommendation: 1; Level of evidence: ØØØØ

590

Recommendation 31*[^]

We recommend that insufficient thyroid replacement should be considered in CeH patients when serum FT4 concentrations are below or close to the lower limit of the normal range, in particular if associated with serum TSH >1.0 mU/L and multiple and persistent hypothyroid manifestations.

Strength of recommendation: 1; Level of evidence: ØØOO

591

Recommendation 32*^

In CeH patients, we recommend to consider up-titration of the L-T4 dose in all conditions listed below:

- retarded psychomotor and cognitive development in infants and children;
- introduction of GH replacement therapy;
- introduction of estrogen replacement therapy or oral contraceptives;
- pubertal development;
- controlled ovarian stimulation;
- pregnancy;
- introduction of treatments impacting LT4 absorption or thyroid hormone metabolism.

In these cases, TSH and FT4 should be measured 4-6 weeks after the up-titration in order to check the adequacy of replacement.

Strength of recommendation: 1; Level of evidence: ØØOO

592

Recommendation 33^

We recommend down-titration of the L-T4 dose in elderly CeH patients, in particular with associated cardiovascular morbidities, and after parturition or menopause, or when the concomitant treatments listed in “recommendation 31” are withdrawn.

In these cases, TSH and FT4 should be measured 4-6 weeks after the down-titration in order to check the adequacy of replacement.

Strength of recommendation: 1; Level of evidence: ØØOO

593

Recommendation 34*^

We recommend that L-T4 overtreatment should be considered in CeH patients when serum FT4 concentrations are above or close to the upper limit of normal (provided that L-T4 is taken after blood withdrawal), in particular if associated with clinical thyrotoxic manifestations, or high T3 concentrations.

Strength of recommendation: 1; Level of evidence: ØØOO

594

595

596

597 **Table 1.** Candidate genes in inheritable forms of Central hypothyroidism (CeH) and related
598 phenotypes.

| Genes (OMIM*) | inheritance and Phenotype (OMIM#) |
|----------------------------|---|
| TSH6 (188540) | Recessively inherited isolated CeH of neonatal onset with low TSH, high α -GSU and normal PRL concentrations, pituitary hyperplasia reversible on L-T4 replacement (275100) |
| TRHR (188545) | Recessively inherited CeH with normal TSH and low PRL concentrations, blunted TSH/PRL responses to TRH, male index cases referred for growth retardation or overweight during childhood, one female proband referred for prolonged neonatal jaundice; no lactation defect in affected women |
| TBL1X (300196) | X-linked mild isolated CeH, normal TSH concentrations, impaired hearing |
| IGSF1 (300137) | X-linked CeH (affecting males and females with skewed X chromosome inactivation), associated with low PRL, variable GH deficiency, metabolic syndrome and post-pubertal macroorchidism (+2.0 SDS) (300888) |
| POU1F1 (173110) | Dominantly or recessively inherited CeH of variable age of onset, combined with GH and PRL defects, prominent forehead, mid face hypoplasia, depressed nose (613038) |
| PROP1 (601538) | Recessively inherited CeH with variable age of onset, combined with GH, PRL, LH/FSH defects, and delayed ACTH deficiency, small to large pituitary volume (262600) |
| HESX1 (601802) | Dominantly or recessively inherited hypopituitarism associated with septo-optic dysplasia (SOD) (182230) |
| SOX3 (313430) | X-linked hypopituitarism, anterior pituitary hypoplasia with ectopic posterior pituitary, persistent cranio-pharyngeal canal and learning difficulties (312000) |
| SOX2 (184429) | Dominantly inherited variable hypopituitarism, pituitary hypoplasia, microphthalmia, variable learning difficulties (206990) |
| OTX2 (600037) | Dominantly inherited hypopituitarism, anterior pituitary hypoplasia with ectopic posterior pituitary, and ocular defects (ano/microphthalmia/retinal dystrophy) (610125) |
| LHX3 (600577) | Recessively inherited hypopituitarism with inconstant ACTH defect, small to large pituitary, short and rigid cervical spine, and variable hearing defect (221750) |
| LHX4 (602146) | Dominant or recessively inherited variable hypopituitarism, anterior pituitary hypoplasia with ectopic posterior pituitary, Arnold-Chari syndrome, corpus callosum hypoplasia (262700) |
| NFKB2 (164012) | Dominantly inherited DAVID syndrome (variable immune deficiency and ACTH defect) with variable GH and TSH deficiency (615577) |
| CHD7 (608892) | Dominantly inherited CHARGE syndrome (coloboma, heart anomaly, choanal atresia, retardation, genital and ear anomalies) with ectopic posterior pituitary and variable LH/FSH, TSH and GH defects, (214800) |
| FGFR1 (136350) | Dominantly inherited Kallmann syndrome (central hypogonadism and anosmia), variable associations with defects of other pituitary hormones including TSH, septo-optic dysplasia and ectopic posterior pituitary |
| FGF8 (600483) | Recessively inherited Kallmann syndrome, variable associations with defects of other pituitary hormones including TSH, holoprosencephaly and corpus callosum agenesis |
| FOXA2 (600288) | Dominant hypopituitarism with craniofacial and endoderm-derived organ abnormalities, and hyperinsulinism, |
| PROKR2 (607123) | Variable hypopituitarism associated with septo-optic dysplasia or pituitary stalk interruption, variable inheritance |
| LEPR | Recessively inherited hyperphagia and obesity, combined with central hypogonadism |

599

600 **Table 2. Causes of central hypothyroidism (CeH)**

| | |
|--|---|
| Invasive and/or compressive lesions of the pituitary sella region | Pituitary macroadenomas Craniopharyngiomas Meningiomas or gliomas Rathke cleft cysts Metastatic seeding Carotid aneurysm |
| Iatrogenic causes | Cranial surgery or irradiation Drugs (eg, rexinoids, mitotane) |
| Injuries | Head traumas Traumatic delivery |
| Vascular accidents | Pituitary infarction Sheehan syndrome Subarachnoid haemorrhage |
| Autoimmune diseases | Post-partum hypophysitis Lymphocytic hypophysitis |
| Infiltrative lesions | Iron overload Sarcoidosis Histiocytosis X |
| Inheritable defects | MPHDs or Isolated CeH |
| Infective diseases | Tuberculosis Mycoses Syphilis |

601

602

603

604

605 **Table 3. Conditions with biochemical features that could lead to an erroneous CeH**
 606 **diagnosis.**

| |
|---|
| Non-thyroidal illness |
| Isolated maternal hypothyroxinaemia (to be interpreted in the context of trimester specific FT4 reference ranges for pregnant women) |
| L-T4 withdrawal syndrome |
| Recovery from thyrotoxicosis |
| Technical assay problems or interference, or defects in Thyroxine binding Globulin (TBG defects in case of total T4 determination or calculation FT4 index) |
| Drugs reducing TSH secretion (glucocorticoids, dopamine, cocaine, anti-epileptics or anti-psychotics, metformin) |
| Premature birth (delayed TSH rise in hypothyroid infants) |
| Allan-Herndon-Dudley syndrome (<i>MCT8</i> mutations) |
| <i>THRA</i> mutations (RTH α) |
| <i>TSHβ</i> mutations with conserved bioactivity but lost immunoreactivity of circulating TSH |

607
 608
 609

610 **Table 4. Tests and findings useful to support the diagnosis of CeH in uncertain**
 611 **conditions.**

| |
|--|
| Evidence of CeH in first-degree relatives |
| Delayed growth, macroorchidism, hearing loss, other signs of hypothyroidism |
| Causative mutation(s) in CeH candidate gene(s) |
| Insufficiency of other pituitary hormone secretion |
| Blunted (<4 mU/L) or delayed (peak after 60 minutes) TSH responses to TRH (200 µg iv) |
| Blunted nocturnal TSH surge |
| Low TSH index [TSHI= log TSH (mU/L) + 0.1345 x FT4 (pM)]* |
| Otherwise unexplained alterations in variables of thyroid hormone action (eg, high cholesterol, bradycardia, low body temperature, echocardiographic findings) |

612

613 * TSHI reference interval: 2.70±0.676 (SD) (see ref. 42)

614

615

616

617

618

619 **Legend to Figure 1**

620

621 **Figure 1.** Flow-chart for the diagnosis and management of CeH.

622 Abbreviations: MRI: magnetic resonance imaging; CeH: central hypothyroidism; MPHD:


623 multiple pituitary hormone defect; ES: empty sella; PSI: pituitary stalk interruption; PID:

624 pituitary infiltrative disease; TBI: traumatic brain injury; VA: vascular accident; IO: iron

625 overload or hemochromatosis; rhGH: recombinant human growth hormone; COS: controlled

626 ovarian stimulation.

627



^a Confirm low FT4 and inappropriately low TSH, and exclude conditions reported in Table 3

^b see Table 1 for details

^c see Table 4 for details

628

629

630

631

632